immunology and virology
Eureka Research Fund for Immunology and Virology is initiated by Eureka TechIN to support the research innovation activities which address the emerging health concerns.
There is an initial commitment of $500K of fund, which will support 3 fields of research:
Antivirus & anti-bacteria
Eureka TechIN will manage this research fund through the process of application review, monitoring and evaluation to generate the R&D outcomes.
We closely work with our advisory board, which consists of experts in medical research and health services/practices, to maintain the high quality of the research.
A/Prof. David Anderson
Deputy Director of Burnet Institute
Head of Global Health Diagnostics Development Laboratory
Founder and CEO of Nanjing BioPoint Diagnostics
Dr. Ruchong Ou
Senior Research Fellow of Monash University
Senior Research Fellow of Alfred Hospital
Prof. Paul Hertzog
Director of the Centre for Innate Immunity and Infectious Diseases
Deputy Director of the Hudson Institute of Medical Research
Founder of the Victoria Infection and Immunity Network
The Eureka research grant can be used for
With the rapid development of COVID-19 virus, the call for first round of application will be focused on anti-virus research.
To be eligible for our research grant, your project must be based in Australia.
Outcomes for 1st round application
To date, the Eureka Research Fund for Immunology and Virology has resulted in the commitment of $200k to fund 4 research teams for Covid-19 related research. Those 4 research teams and their projects listed below,
A novel metabolite to treat virus-induced acute respiratory distress syndrome (ARDS)
Prof. Ben Marsland and his team, Monash University
Age Matters? Correlation of CoViD-19 Infection Severity with the Immune and Microbiome state in Children, Adults and Elderly
Dr. Samuel Forster and his team, Hudson Institute of Medical Research
Modeling the immune pathogenesis of COVID-19 severity for target immunotherapy
Prof. Di Yu and his team, The University of Queensland
Antibody neutralization assays for SARS-CoV-2 to measure vaccine- and naturally-acquired antibody responses
Prof. Heidi Drummer and her team, Burnet Institute